CymaBay Therapeutics Inc. (CBAY) Financial Statements (2024 and earlier)

Company Profile

Business Address 7575 GATEWAY BOULEVARD
NEWARK, CA 94560
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:213,800236,400135,500153,400170,800193,400
Cash and cash equivalents35,48259,15020,29130,69152,75373,995
Short-term investments178,362177,215115,194122,724111,130114,564
Other undisclosed cash, cash equivalents, and short-term investments(44)3515(15)6,9174,841
Prepaid expense    1,0411,6252,103
Other undisclosed current assets10,2716,3202,573683(5,814)(3,457)
Total current assets:224,071242,720138,073155,124166,611192,046
Noncurrent Assets
Operating lease, right-of-use asset99137169197220239
Property, plant and equipment6267297018459931,024
Long-term investments and receivables     6,8744,885
Long-term investments     6,8744,885
Other noncurrent assets1,8541,7332,9093,0813,0262,448
Total noncurrent assets:2,5792,5993,7794,12311,1138,596
TOTAL ASSETS:226,650245,319141,852159,247177,724200,642
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,9739,50114,6906,08911,5546,461
Employee-related liabilities3,0112,081
Accounts payable4,5891,6331,096479866199
Accrued liabilities10,3847,86813,5945,6107,6774,181
Deferred revenue1,63233,733    
Other undisclosed current liabilities1,2893,2667516,6221,0067,578
Total current liabilities:17,89446,50015,44112,71112,56014,039
Noncurrent Liabilities
Long-term debt and lease obligation:    206374537
Liabilities, other than long-term debt1,100 30   
Deferred revenue1,100     
Operating lease, liability   30206374537
Other undisclosed noncurrent liabilities99,24894,63090,22785,94681,95978,148
Total noncurrent liabilities:100,34894,63090,25786,35882,70779,222
Total liabilities:118,242141,130105,69899,06995,26793,261
Equity
Equity, attributable to parent108,408104,18936,15460,17882,457107,381
Common stock17178888
Additional paid in capital1,010,9581,005,877909,329906,968904,609902,217
Accumulated other comprehensive loss(124)(70)(326)(574)(441)(219)
Accumulated deficit(902,443)(901,635)(872,857)(846,224)(821,719)(794,625)
Total equity:108,408104,18936,15460,17882,457107,381
TOTAL LIABILITIES AND EQUITY:226,650245,319141,852159,247177,724200,642

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues 31,016     
Gross profit: 31,016     
Operating expenses(31,115)(26,875)(23,477)(21,363)(23,769)(24,502)
Operating loss:(99)(26,875)(23,477)(21,363)(23,769)(24,502)
Nonoperating expense(709)(1,903)(3,156)(3,142)(3,325)(3,267)
Investment income, nonoperating2,6272,01391967732198
Other nonoperating income (expense)1,282487  2 
Interest and debt expense(4,618)(4,403)(4,075)(3,819)(3,648)(3,365)
Loss from continuing operations:(5,426)(33,181)(30,708)(28,324)(30,742)(31,134)
Loss before gain (loss) on sale of properties:(28,324)(30,742)(31,134)
Other undisclosed net income  4,4034,075  3,365
Net loss:(5,426)(28,778)(26,633)(28,324)(30,742)(27,769)
Other undisclosed net income attributable to parent4,618  3,8193,648 
Net loss available to common stockholders, diluted:(808)(28,778)(26,633)(24,505)(27,094)(27,769)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(5,426)(28,778)(26,633)(28,324)(30,742)(27,769)
Other comprehensive income (loss)(54)256248(133)(222)(206)
Comprehensive loss:(5,480)(28,522)(26,385)(28,457)(30,964)(27,975)
Other undisclosed comprehensive income, net of tax, attributable to parent4,618  3,8193,648 
Comprehensive loss, net of tax, attributable to parent:(862)(28,522)(26,385)(24,638)(27,316)(27,975)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: